Cell-autonomous inflammation of BRCA1-deficient ovarian cancers drives both tumor-intrinsic immunoreactivity and immune resistance via STING.
Cell Rep. 2021 Jul 20;36(3):109412. doi: 10.1016/j.celrep.2021.109412.
Cell Rep. 2021.
PMID: 34289354
Free PMC article.